DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Double Blind Clinical Trial of DCS for Food Anxiety

Information source: Washington University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anorexia and Bulimia Nervosa

Intervention: Sertaline (Drug)

Phase: N/A

Status: Completed

Sponsored by: Washington University School of Medicine

Summary

This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS relative to placebo condition (c) participants in the DCS condition will have a greater increase in Body Mass Index.

Clinical Details

Official title: A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Anxiety

Secondary outcome: Body Mass Index

Eligibility

Minimum age: 14 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise

Specified Exclusion Criteria:

- Pregnant or planning on becoming pregnant

- Psychotic or Manic

Locations and Contacts

Washington University, Saint Louis, Missouri 63130, United States
Additional Information

Starting date: February 2013
Last updated: December 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017